Mitoxantrone-DHAP with GM-CSF: An active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 35, Issue 5-6, 1999, Pages 527-536

  Haq, Rashida ^b,c   Sawka, Carol A ^a,c,d   Franssen, Edmée ^a   Berinstein, Neil L ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

M DHAP + GM CSF; Relapsed lymphoma; Salvage treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPHIL; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; SALVAGE THERAPY; SEIZURE; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; VEIN THROMBOSIS; VOMITING;

EID: 0033396868     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428199909169617     Document Type: Article

References (37)

1. Fisher, R.I., Gaynor, E.R., Dahlberg, S., et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England Journal of Medicine, 328, 1002-1006.
2. Velasquez, W.S., Cabanillas, F., Salvador, P. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117-122.
3. Nichols, C.R., P.J. L., Greist, A., et al (1988) Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. Medical and Pediatric Oncology, 16, 12-16.
4. Dana, B., Dahlberg, S., Schnitzer, B., et al (1989) Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group Phase II trial. Investigational New Drugs, 7, 247-250.
5. Comella, P., Abate, G., Di Finizio, G., et al (1990) Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin. Cancer Chemotherapy and Pharmacology, 26, 306-309.
6. Goss, P.E., Sheperd, F.A., Scott, J.G., et al (1991) Dexamethasone, ifosfamide, cisplatin, etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II study. Annals of Oncology, 2, 43-46.
7. Paciucci, P.A., Crown, J.C., Holland, J.F. (1989) Mitoxantrone, Vincristine, and Dexamethasone in patients with refractory lymphoma. American Journal of Clinical Oncology, 12, 327-331.
8. Silver, R.T., Case, Jr. D.C., Wheeler, R.H., et al (1991) Multicenter clinical trial of mitoxantrone in non-Hodkin's lymphoma and Hodkin's Disease. Journal of Clinical Oncology, 9, 754-761.
9. 3-ARA C: An effective salvage regimen in refractory or recurrent aggressive non-Hodgkin's lymphoma. A report on 18 cases. Haematological Oncology, 9, 259-266.
10. Cabanillas, F., Hagemeister, F.B., McLaughlin, P., et al (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology, 5, 407-412.
11. Cabanillas, F., Hagemeister, F.B., Bodey, G.P., et al (1982) IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood, 60, 693-697.
12. Hayat, M., Ostronoff, M., Gilles, E., et al (1990) Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. Cancer Investigation, 8, 1-5.
13. Stewart, A.K., J.M. B., Sutcliffe, S.B. (1991) Mini-Beam as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma. Leukemia and Lymphoma, 5, 111-115.
14. Philip, T., Armitage, J.O., Spitzer, G., et al (1987) High dose therapy and ABMT after failure of conventional chemotherapy in adults with intermediate grade or high grade NHL. The New England Journal of Medicine, 316, 1493-1498.
15. Appelbaum, F.R., Sullivan, K.M., Buckner, C.D. (1987) Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology, 5, 1340-1347.
16. Phillips, G.L., Fay, J.W., Herzig, R.H. (1990) The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood, 75, 831-838.
17. Peterson, F.B., Appelbaum, F.R., Hill, R. (1990) Autologous marrow transplantation tor malignant lymphomas. A report of 101 cases from Seattle. Journal of Clinical Oncology, 8, 638-647.
18. Takvorian, T., Canellos, G.P., Ritz, J. (1987) Prolonged disease-free survival after ABMT in patients with NHL with poor prognosis. The New England Journal of Medicine, 316, 1499-1505.
19. Freedman, A.S., Takvorian, T., Anderson, K.C. (1990) Autologous bone marrow transplantation in B-cell NHL: Very low treatment related mortality in 100 patients with sensitive relapse. Journal of Clinical Oncology, 8, 784-791.
20. Canellos, G.P., Nadler, L., Tak, T. (1988) Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Seminars in Hematology, 25, 58-65.
21. Bosly, A., Coiffier, B., Gisselbrecht, C. (1993) Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's lymphoma: the GELA experience. Nouvelle Revue Française d'Hématologie, 35, 21-23.
22. Cortelazzo, S., Viero, P., Bellavita, P. (1995) Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. Journal of Clinical Oncology, 13, 935-94.
23. Klumpp, T.R., Mangan, K.F., Goldberg, S.L., et al (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. Journal of Clinical Oncology, 13, 1323-1327.
24. Philip, T., Hartmann, O., Biron, P. (1988) High dose therapy and autologous bone marrow transplantation in partial response after first line induction therapy for diffuse NHL. Journal of Clinical Oncology, 6. 1118-1124.
25. Philip, T., Chauvin, F., Armitage, J., et al (1991) Parma International Protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood, 77, 1587-1592.
26. Philip, T., Gugliemi, C., Chauvin, F. (1995) Autologous Bone Marrow transplantation (ABMT) versus (vs) conventional chemotherapy (DHAP) in relapsed non-Hodgkin's lymphoma (NHL); final analysis of the PARMA randomized study (216 patients). (Abstr). Proceedings of the American Society of Clinical Oncology, 14.
27. Neidhart, J.A., Kubica, R., Stidley, C. (1994) Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma. Cancer Investigation, 12, 1-11.
28. Meyer, R.M., Hryniuk, W.M., Goodyear, M.D. (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 9, 339-347.
29. Skipper, H.E., Schabel, Jr. F.M., Wilcox, W.S. (1964) Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemotherapy Reports, 35, 1.
30. Frei, III E., Teicher, B.A., Holden, S.A. (1988) Preclinical studies and clinical correlation of the effect of Alkylator dose. Cancer Research, 48, 6417.
31. Press, O.W., Livingston, R., Mortimer, J., et al (1991) Treatment of relapsed non-Hodgkin's lymphomas with DHAP before bone marrow transplantation. Journal of Clinical Oncology, 9, 423-431.
32. Montillo, M., Tedeschi, A., Capelli, D., et al (1995) Efficacy of DHAP regimen in relapsed and refractory lymphomas with or without major ablative therapy (Abstr). Proceedings of the American Society of Clinical Oncology, 14, 400.
33. Neidhart, J.A. (1993) Pixy 321 support of chemotherapy with carboplatin and dose intensive cytoxan, Vp-16 and cisplatin (DICEP). Biotechnology and Therapies.
34. Velasquez, W., Hagemeister, F., McLaughlin, P., et al (1992) E-SHAP: An effective treatment tor refractory and relapsing lymphoma. A long follow-up (Abstr). Proceedings of the American Society of Clinical Oncology, 11, 326
35. Johnson, P.W.M., Sweetenham, J.W., McCallum, P., et al (1993) E-SHAP: Inadequate treatment for poor-prognosis recurrent lymphoma. Annals of Oncology, 4, 63-67.
36. Aparicio, U.J., Gomez, C.J., Molins, P.C. (1993) Quimioterapia de rescate en la enfermedad de Hodgkin y los linfomas no hodgkinianos con etoposido, metilprednisolona, allas dosis de ara-C y cisplatino (E-SHAP). Neoplasia, 10, 48-53.
37. Ezzat, A.A., Khalifa, F., Berry, J., et al (1994) E-SHAP: An effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Proceedings of the American Society of Clinical Oncology, 13, 383.